Janney Analyst Starts Clovis Oncology At Buy, Expects Regulatory Approvals Coming In 2016

By: via Benzinga
The share price of Clovis Oncology Inc (NASDAQ: CLVS) has appreciated 7.57 percent in the last month, after having fallen 70.08 ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.